Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S1XO
|
|||
| Former ID |
DIB002185
|
|||
| Drug Name |
BIBX-79
|
|||
| Synonyms |
175033-26-8; BIBX-79; AC1L9UY2; BIBX 79; SCHEMBL8046646; SCHEMBL3363189; CHEMBL2377448; CHEMBL3765649; MolPort-028-951-512; ZINC59696570; ZINC238856506; ZINC100502012; AKOS034800865; MCULE-9414485243; EN300-155171; Z1768160684; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methyl-benzamide; 4-chloro-N-[4-[4-(dimethylaminomethyl)phenyl]cyclohexyl]-N-methylbenzamide; 4-Chloro-N-[4-(4-dimethylaminomethyl-phenyl)-cyclohexyl]-N-methyl-benzamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Arteriosclerosis [ICD-11: BD40; ICD-9: 440] | Terminated | [1] | |
| Company |
Boehringer Ingelheim Corp
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H29ClN2O
|
|||
| Canonical SMILES |
CN(C)CC1=CC=C(C=C1)C2CCC(CC2)N(C)C(=O)C3=CC=C(C=C3)Cl
|
|||
| InChI |
1S/C23H29ClN2O/c1-25(2)16-17-4-6-18(7-5-17)19-10-14-22(15-11-19)26(3)23(27)20-8-12-21(24)13-9-20/h4-9,12-13,19,22H,10-11,14-16H2,1-3H3
|
|||
| InChIKey |
WBNUHWUTAHSPER-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lanosterol synthase (LSS) | Target Info | Modulator | [1], [2] |
| BioCyc | Cholesterol biosynthesis II (via 24,25-dihydrolanosterol) | |||
| Cholesterol biosynthesis III (via desmosterol) | ||||
| Cholesterol biosynthesis I | ||||
| Superpathway of cholesterol biosynthesis | ||||
| Lanosterol biosynthesis | ||||
| KEGG Pathway | Steroid biosynthesis | |||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Panther Pathway | Cholesterol biosynthesis | |||
| Pathwhiz Pathway | Steroid Biosynthesis | |||
| Reactome | Cholesterol biosynthesis | |||
| Activation of gene expression by SREBF (SREBP) | ||||
| WikiPathways | Activation of Gene Expression by SREBP (SREBF) | |||
| SREBP signalling | ||||
| Cholesterol Biosynthesis | ||||
| Cholesterol biosynthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. J Lipid Res. 1996 Jan;37(1):148-58. | |||
| REF 2 | Toxicologic lesions associated with two related inhibitors of oxidosqualene cyclase in the dog and mouse. Toxicol Pathol. 2001 Mar-Apr;29(2):174-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.